EPIDEMIOLOGY AND IMMUNOVIROLOGY OF HTLV-I AND II (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

EPIDEMIOLOGY AND IMMUNOVIROLOGY OF HTLV-I AND II (MEETING ABSTRACT)

Fifteenth Symposium of the International Association for Comparative Research on Leukemia and Related Diseases. October 6-11, 1991, Padova/Venice, Italy, p. 15, 1991.. Unique Identifier : AIDSLINE ICDB/92682371
De The G; Epidemiology of Oncogenic Viruses Unit, Institut Pasteur, Paris,; France

Abstract: Since their discovery 10 yr ago, essential information has been obtained on the human oncoretroviruses HTLV-I and HTLV-II. Their long-standing presence in human populations in America and Africa suggests that physiological controls kept these infections latent. Their pathogenic potential needs specific conditions and cofactors. We review the association between HTLV-I and adult T-cell leukemias, encephalomyelopathies (observed not only in endemic areas of Japan, Africa, the Caribbean basin and South America, but also as iatrogenic events associated with blood transfusion), as well as polymyositis, arthropathies, dermatitis. Oncoretrovirus-associated pathologies in animals reflect the interplay between viruses, environmental factors and specific genetic susceptibility of the host. The lack of effective curative treatment of these HTLV-I-associated pathologies and the genomic stability of these oncoretroviruses make the development of a vaccine attractive from a public health point of view. Furthermore, the possible role of HTLV-I as cofactor in AIDS development, makes such a vaccine development of public health interest in certain areas.

Keywords: Brain Diseases/ETIOLOGY Dermatitis/COMPLICATIONS Genome, Viral Human HIV Infections/*COMPLICATIONS/GENETICS/PREVENTION & CONTROL *HTLV-I *HTLV-II Joint Diseases/COMPLICATIONS Leukemia, T-Cell/COMPLICATIONS Myositis/COMPLICATIONS Viral Vaccines ABSTRACT
920930
M9290921

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .